Lenalid 25 Capsule contains Lenalidomide 25 mg, an immunomodulatory agent used primarily in the treatment of multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma. Lenalidomide exerts its therapeutic effects by modulating the immune system, inhibiting angiogenesis, and inducing apoptosis in malignant cells. It is indicated for patients with multiple myeloma who have received at least one prior therapy, as well as for transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with deletion 5q cytogenetic abnormality. The capsule should be administered orally once daily, with or without food, as prescribed by a healthcare professional. Dose adjustments may be necessary based on renal function and hematologic response. Common adverse effects include neutropenia, thrombocytopenia, fatigue, and rash, necessitating regular monitoring of blood counts and clinical status. Lenalid 25 Capsule is contraindicated in pregnancy due to its teratogenic potential and requires strict adherence to risk management programs to prevent fetal exposure. Patients should be counseled on potential side effects and the importance of compliance with prescribed dosing and monitoring protocols to optimize therapeutic outcomes and minimize risks.